Canakinumab (ILARIS), as a biological agent, is widely used in clinical practice for the treatment of various inflammatory diseases, such as periodic fever syndromes, hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial Mediterranean fever (FMF), and Still's disease, etc. 

Adverse effects of Canakinumab (ILARIS)

The following will elaborate on the possible adverse reactions of canakinumab in the treatment of different diseases.

Adverse Reactions in Periodic Fever Syndromes

In the treatment of periodic fever syndromes, although canakinumab can effectively control the condition, it may also cause a series of adverse reactions. Among them, nasopharyngitis, diarrhea, flu-like symptoms, rhinitis, nausea, headache, etc., are relatively common, with an incidence rate exceeding 10%. In addition, bronchitis, gastroenteritis, pharyngitis, weight gain, musculoskeletal pain, and dizziness are also adverse reactions that cannot be ignored. These adverse reactions may have a certain impact on patients' daily lives. Therefore, when using canakinumab, doctors should pay close attention to patients' responses and take timely measures to alleviate the symptoms.

Adverse Reactions in HIDS/MKD, FMF and Other Diseases

For patients with hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial Mediterranean fever (FMF) and other similar diseases, canakinumab is also an effective treatment. However, during the treatment process, patients may experience adverse reactions such as injection site reactions and nasopharyngitis, with the incidence rate reaching or exceeding 10%. Before administration, doctors should fully inform patients of these potential risks and take corresponding preventive measures to reduce the occurrence of adverse reactions.

Adverse Reactions in Still's Disease

Canakinumab has also shown certain efficacy in the treatment of Still's disease. However, its adverse drug reactions cannot be ignored. Infections (especially nasopharyngitis and upper respiratory tract infections), abdominal pain, and injection site reactions are the most common adverse reactions in Still's disease patients using canakinumab, with an incidence rate exceeding 10%. These adverse reactions may aggravate the patient's condition and even affect the treatment effect. Therefore, when using canakinumab to treat Still's disease, doctors should strictly control the dosage, closely monitor changes in the patient's condition, and adjust the treatment plan in a timely manner.